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Background: Diabetic nephropathy (DN) is the leading cause of end-stage renal 
disease. The aim of the current study is to investigate the possible beneficial effects 
of Hyphaene thebaica in DN.
Materials and methods: For this, 50 male albino rats were divided into five 
groups: group I — represented the control group; group II — received Hyp-
haene thebaica extracts of 150 mg/kg BW by oral gavage for 6 weeks; group III 
— received single intraperitoneal injections of streptozotocin (50 mg/kg BW) 
to induce type-2 diabetes mellitus; group IV (protective) — diabetic rats recei-
ved Hyphaene thebaica extract (150 mg/kg BW) orally for 6 weeks; group V 
(curative) — received Hyphaene thebaica extract (150 mg/kg BW) orally after the 
diagnosis of DN. 
Results: In the DN protected group, blood glucose, urea, and creatinine decreased 
significantly, while insulin and C-peptide increased significantly. Moreover, cystatin C 
and neutrophil gelatinase-associated lipocalin decreased. Collagen fibre deposi-
tion is increased with an apparent thickening of the parietal layer of Bowman’s 
capsules and the basal lamina of convoluted tubules, as well as increase of the 
immune-reaction of caspase-3 and desmin. The introduction of Hyphaene thebaica 
led to greater amelioration in the biochemical markers, apoptotic alterations, and 
podocyte injuries of the protected group than in the curative group. 
Conclusions: Hyphaene thebaica may be advised as a good choice that can delay 
diabetic renal complications. (Folia Morphol 2015; 74, 4: 447–457)
Key words: diabetic nephropathy, Hyphaene thebaica, podocyte injury, 
apoptosis
INTRODUCTION
Diabetes mellitus is one of the most common 
disease affecting the populations around the world. 
Roughly 285 million individuals are diabetic worldwi-
de, and this number is expected to increase 54% by 
2030 [42]. Diabetic nephropathy (DN), a renovascular 
complication that affects nearly 30% of diabetics and 
leads to an end-stage renal disease, is a common 
microvascular complication of type 2 diabetes mellitus 
[21]. The early diagnosis of DN is crucial to avoid the 
destructive outcomes of renal failure among diabetics 
[27]. While microalbuminuria has been recognised as 
a significant predictive marker for the early diagnosis 
of DN [27], some diabetics may develop DN without 
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an apparent microalbuminuria [18]. Therefore, sens-
itive and specific markers are required to detect DN 
in its early stages [27]. 
Cystatin C (Cys C) is considered as an important 
marker for DN, which represent a preferable substitu-
te for serum creatinine in the estimation of glomerular 
filtration rates, especially in evaluating the prognosis 
of chronic renal diseases [17]. Neutrophil gelatinase-
-associated lipocalin (NGAL) is a biomarker expressed 
in numerous human tissues, including the kidney, and 
is of significant expression within injured epithelia 
[39]. NGAL genes have been found to be strongly 
expressed following renal ischaemic or nephrotoxic 
injuries in animal models [36]. NGAL can be detected 
both in the blood and urine and has been conside-
red to be an early predictor of acute kidney injury in 
various clinical disorders [32].
The World Health Organisation has encouraged 
research on medicinal plants as antidiabetics [1, 37]. 
Hyphaene thebaica is an African palm tree common 
in Upper Egypt [3], the fruit contains significant 
amounts of saponins, coumarins, hydroxycinnamates, 
essential oils, flavonoids, alkaloids, reducing sugars, 
glycosides, and water-soluble phenolic contents with 
powerful antioxidant activity [15].
The fruit of the Hyphaene thebaica, known as 
a famine food, is considered a life-sustaining nutrient 
in desert areas, especially during periods of drought 
[15]. The plant is known to possess phytochemical 
constituents with antidiabetic capacities [1]. Phenolics 
and oxylipids within the plant were determined using 
UPLC-PDA-TOF (ultra-performance-photodiode array-
-time of flight) high-resolution mass spectrometry 
in order to obtain their molecular formula and their 
exact mass under-optimised conditions. Seventeen 
compounds were identified and quantified from the 
fruit of Hyphaene thebaica, including 2 cinnamic 
acid derivatives, 5 flavonoids, 6 fatty acids, 2 sphin-
golipids, a lignan, and a stilbene. The plant’s sugar 
composition was characterised and quantified by 
1H-nuclear magnetic resonance, with sucrose detec-
ted as its major component at a level of 219 mg/g [3].
Hyphaene thebaica has an antioxidant activity 
due to the substantial amount of water-soluble phe-
nolic contents of flavonoids within it. These contents 
represent conjugates of o-glycosides, which include 
quercetin, chrysoeriol, luteolin, and isorhamnetin H 
[1, 15]. Moreover, Hyphaene thebaica is known to 
possess anti-inflammatory capacities due to its ability 
to inhibit cyclooxygenase (COX-1), an enzyme known 
to be involved in the inflammation [37]. Therefore, the 
present work aims to study the protective and curative 
effects of Hyphaene thebaica extract on induced DN.
MATERIALS AND METHODS
Plant material. The Hyphaene thebaica (doum) 
fruit was obtained from local markets in Giza, Egypt.
Preparation of extracts. The fruits was cleaned 
and separated into pulp. The pulp was then dried 
and ground into powder, which was sieved through 
a 0.25 mm sieve (Endecott Test Sieves Ltd., London, 
UK). Subsequently, 50 g of the powder was extracted 
and treated with 100 mL of ethyl alcohol overnight. 
In order to obtain the dried extracts, the solvents 
were left to evaporate spontaneously. Aqueous sus-
pension was performed by suspending 50 g of the 
powdered pulp in 100 mL of distilled water and 
stored at a low temperature. The suspension was 
then shaken vigorously to obtain a homogenous 
mixture before the oral administration of Hyphaene 
thebaica extracts [1].
Animals. Adult male albino rats of the Sprague-
-Dawley strain weighing 175–210 g were obtained 
from the animal house of the National Research 
Centre (NRC) in Giza, Egypt. The rats were housed 
individually in stainless steel cages at 22 ± 2°C under 
a light/dark cycle and allowed to acclimatise for a pe-
riod of 7 days before the experiment with free access 
to food and water ad labium. All work followed the 
recommendations of the National Institute’s Guide 
for the Care and Use of Laboratory Animals and was 
approved by the Animal Ethical Committee of the 
NRC in Cairo, Egypt.
Induction of type 2 diabetes mellitus. Diabetes 
was induced in fasted rats overnight via intraperitone-
al single injections of freshly prepared streptozotocin 
(50 mg/kg BW) dissolved in citrate buffer (pH 4.5). 
Rats were considered diabetic if their fasting blood 
sugar measured after 72 h exceeded 250 mg/dL [46].
Experimental design. 50 rats were divided into 
the following five groups of ten rats each:
— group I (the control group): received 0.1 M citrate 
buffer pH (4.5) for 6 weeks [29];
— group II: received Hyphaene thebaica extract 
150 mg/kg BW by oral gavage for 6 weeks [1];
— group III (DN group): included diabetic nephro-
pathy without treatment;
— group IV (prophylactic group): diabetic rats re-
ceived the same dose of Hyphaene thebaica ex-
tract orally for 6 weeks immediately after being 
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diagnosed as diabetic as a protective against the 
consequences of diabetes, including nephropathy;
— group V (curative group): diabetic rats received 
the same dose of Hyphaene thebaica orally for 
3 weeks upon being diagnosed with nephropathy 
at the 4th week [6, 40]. 
Sample collection. At the end of experiment, 
blood samples were collected from the retro-orbital 
plexuses of veins using capillary tubes. The samples 
were centrifuged at 3000 rpm for 15 min to separate 
the serum. The serum was then frozen at –20°C for 
the subsequent estimation of biochemical parameters.
Analysis of biochemical indices. Serum glu-
cose levels were measured using enzymatic co-
lorimetric methods with commercial kits (Randox 
Laboratories, Ltd., Antrim, UK). Serum urea and 
creatinine levels were assayed spectrophotometri-
cally according to standard procedures using com-
mercial diagnostic kits supplied by the Biodiagno-
stic Company (Cairo, Egypt). Serum insulin levels 
were determined by enzyme-linked immunosor-
bent assay (ELISA) using the Boehringer-Mannheim 
kit with a Boehringer model ES300 analyser (Bo-
ehringer, Germany). Serum C-peptide levels were 
determined using a quantitative solid-phase ELISA 
using kits from the Immunospec Co., USA. Serum Cys C 
and serum NGAL were determined quantitatively 
using ELISA kits supplied from Glory Science Co., USA.
Histological study. The rats were sacrificed by de-
capitation and renal samples were preserved in 10% 
neutral buffered formalin. Samples of 5 μm thickness 
were prepared and stained with Haematoxylin and 
Eosin (H&E) for routine exam and with Masson’s Tri-
chrome to visualise the collagen fibres. Then observed 
using an Olympus BX53 microscope equipped with 
a DP73 camera (Olympus, Tokyo, Japan) [28, 41].
Immunohistochemical study. The renal samples 
were immunostained using primary antibodies cas-
pase-3 (a marker for apoptosis; rabbit polyclonal, 
Cat. no. 250573, Abbiotec-San Diego, USA; dilution 
1: 200) and desmin (a marker for podocyte injury; mo-
noclonal mouse antibody, Lab Vision Corp, NeoMar-
kers Inc/Lab Vision, Fremont, California, USA; dilution 
1: 100) according to the manufacturers’ guidelines. 
The avidin-biotin complex peroxidase method was 
used for the immunohistochemical study. Sections 
were incubated for 20 min in DAB chromogen (3,30 
diaminobenzidine) and then counter-stained with 
Mayer’s haematoxylin. For positive control sections, 
standard laboratory slides were used for all stains 
to validate the success of the immunohistochemical 
technique. All slides were examined under light mic-
roscopy and the presence of labelled cells was docu-
mented. The absence of staining was recognised as 
a negative result, while the presence of brown staining 
was recognised as a positive result [16].
Morphometrical analysis. 20 non-overlapping 
fields from the ten rats in each experimental group 
were randomly selected. Renal parameters were ana-
lysed in terms of the diameter of the renal corpuscle 
and urinary space (of nearly round sections) using the 
Image-Pro Plus v6.0 (Media Cybernetics, Maryland, 
USA) and ImageJ software v1.49n (NIH) to confirm the 
analysis outcomes. Furthermore, the mean percenta-
ge area of positive immune cells was calculated and 
analysed for comparison with the control group [16]. 
Statistical analysis. The data analysis was carried 
out using the Statistical Package of Social Science 
software version 22 (SPSS Inc., Chicago, IL, USA). All 
numeric variables were expressed as mean ± standard 
deviations (SD). Statistical comparisons were perfor-
med using one-way analysis of variance (ANOVA) 
tests followed by post-hoc least significant difference 
for multi-group comparisons. The homogeneity of 
variance was assessed using Levene’s test. Differences 
were considered significant if p < 0.05 [28].
RESULTS
The results of this study showed the significant 
elevation of glucose, urea, and creatinine serum le-
vels in the untreated DN, prophylactic, and curati-
ve groups compared with the control and control 
Hyphaene thebaica groups. Treatment with Hyphaene 
thebaica in the prophylactic and curative groups in-
duced a significant decrease in the serum levels of 
glucose, urea, and creatinine compared with the 
untreated DN group. However, these levels in the 
latter were still significantly higher than those of 
the control and control Hyphaene thebaica groups. 
Moreover, a significant decrease was found in the 
serum levels of glucose, urea, and creatinine in the 
prophylactic group compared with the curative group 
(Table 1, Fig. 1).
In the DN, prophylactic, and curative groups, serum 
levels of insulin and C-peptide were found to be signifi-
cantly decreased, and serum levels of Cys C and NGAL 
were found to be significantly increased compared with 
the control and control doum groups. In the prophyla-
ctic and curative groups, the serum levels of insulin and 
C-peptide were found to be significantly increased, and 
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the serum levels of Cys C and NGAL were found to be 
significantly decreased compared with the DN group. 
Moreover, a significant increase in the serum levels of 
insulin and C-peptide in the prophylactic group, and 
a significant decrease in the serum levels of Cys C and 
NGAL were found compared with the curative group 
(Table 2, Fig. 2).
Histological results. The regular histological ar-
chitecture was demonstrated in the control group 
and the group treated with Hyphaene thebaica only 
(Fig. 3A). The DN group showed varying degrees of 
deterioration in the histological architecture, with 
apparently increased glomeruli sizes, including con-
gested capillary vessels, vacuolar degeneration of 
the tubules, hyaline casts, and certain tubules with 
distorted cellular boundaries and areas of extravasa-
ted blood cells (Fig. 3B). The group protected from 
DN by Hyphaene thebaica revealed nearly normal 
renal architectures and minimal alterations, no hyali-
ne casts, no extravasated blood cells, and reduction 
of glomerular congestion (Fig. 3C). DN treated with 
Hyphaene thebaica displayed no observable impro-
vement in the histological alterations of the glo-
meruli and tubules (Fig. 3D). The results showed 
a significant elevation of renal corpuscle diameters in 
the untreated DN, prophylactic, and curative groups 
when compared with the control group. Treatment 
with Hyphaene thebaica in the prophylactic and cu-
rative groups induced a significant decrease in renal 
corpuscle diameter compared with the untreated 
DN group (Table 3, Fig. 4). Non-significant changes 
were found in terms of urinary space diameter in the 
studied groups.
The deposition of regular collagen fibres in the 
mesangial matrix of the glomeruli, the boundaries of 
Bowman’s capsules, and around the basal lamina of 
the tubules was observed in the control group and the 
group treated with Hyphaene thebaica only (Fig. 5A). 
The DN group showed an increase in collagen fibre 
Table 1. Comparison of blood glucose and serum levels of urea and creatinine in different studied groups
Parameters Control group Control doum group DN group Prophylactic group Curative group
Serum glucose [mg/dL] 96.00 ± 13.08 95.00± 10.54 250.00 ± 37.71 150.00 ± 18.86 188.00 ± 47.80
1p < 0.0001 1p < 0.0001 1p < 0.0001
2p < 0.0001 2p < 0.0001 2p < 0.0001
3p < 0.0001 3p < 0.0001
4p < 0.006
Serum urea [mg/dL] 14.19 ± 5.15 15.25 ± 4.65 77.40 ± 11.45 48.33 ± 9.49 69.33 ± 4.58
1p < 0.0001 1p < 0.0001 1p < 0.0001
2p < 0.0001 2p < 0.0001 2p < 0.0001
3p < 0.0001 3p < 0.022
4p < 0.0001
Serum creatinine [mg/dL] 1.14 ± 0.33 1.31 ± 0.30 6.61 ± 1.87 3.01 ± 1.02 5.00 ± 1.35
1p < 0.0001 1p <0.032 1p < 0.0001
2p < 0.0001 2p < 0.050 2p < 0.0001
3p < 0.0001 3p < 0.0003
4p < 0.0001
Values are presented as mean ± standard deviation; 1p — significance vs. control group; 2p — significance vs. control doum group; 3p — significance vs. diabetic nephropathy (DN) 
group; 4p — significance vs. prophylactic group; N = 10 for each group
Figure 1. Comparison of blood glucose and serum levels of urea 
and creatinine in different studied groups.
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deposition with seemingly thickened parietal layers 
in Bowman’s capsules and the basal lamina of convo-
luted tubules, as well as patchy areas of connective 
tissue around congested dilated blood vessels and 
vacant areas between certain tubular cells and the 
basal lamina (Fig. 5B). The group protected from DN 
by Hyphaene thebaica revealed a slight increase in 
collagen fibres compared with the control group, yet 
this increase was still less than that of the diabetic 
group and included no remarkable changes in terms 
of glomerular basal lamina thickness or change in 
the basal lamina of convoluted tubules (Fig. 5C). The 
DN group treated with Hyphaene thebaica displayed 
increased collagen deposition in the glomeruli, surro-
unding Bowman’s capsules, and near the convoluted 
tubules, with both mesangial (global or segmental) 
and diffuse thickening of the capillary walls (Fig. 5D).
Immunohistochemical results. The negative cy-
toplasmic staining of the caspase-3 was noticed in 
the control group as well as the group treated with 
Hyphaene thebaica only (Fig. 6A). In the untreated 
DN group, caspase-3 showed a strong immunore-
action (Fig. 6B). In the group protected from DN 
Table 2. Comparison of serum levels of insulin, C-peptide, cystatin C and neutrophil gelatinase-associated lipocalin in different studied 
groups
Parameters Control group Control doum group DN group Prophylactic group Curative group
Serum insulin [mIU/L] 6.17 ± 2.16 7.09 ± 2.69 0.27 ± 0.13 2.26 ± 1.66 1.10 ± 0.91
1p < 0.0001 1p < 0.0001 1p < 0.0001
2p < 0.0001 2p < 0.0001 2p < 0.0001
3p < 0.015 3p = 0.298
4p = 0.148
Serum C-peptide [ng/mL] 1.16 ± 0.21 1.26 ± 0.49 0.24 ± 0.11 0.72 ± 0.19 0.44 ± 0.24
1p < 0.0001 1p < 0.001 1p < 0.0001
2p < 0.0001 2p < 0.0001 2p < 0.0001
3p < 0.0001 3p = 0.114
4p < 0.029
Serum cystatin C [mmol/L] 3.42 ± 0.52 3.78 ± 0.24 26.5 ± 0.91 15.12 ± 0.82 19.24 ± 0.49
1p < 0.0001 1p < 0.0001 1p < 0.0001
2p < 0.0001 2p < 0.0001 2p < 0.0001
3p < 0.0001 3p < 0.0001
4p < 0.0001
Serum NGAL [ng/mL] 0.50 ± 0.01 0.52 ± 0.01 1.69 ± 0.25 1.03 ± 0.15 1.45 ± 0.03
1p < 0.0001 1p < 0.0001 1p < 0.0001
2p < 0.0001 2p < 0.0001 2p < 0.0001
3p < 0.0001 3p < 0.0001
4p < 0.006
Values are presented as mean ± standard deviation; 1p — significance vs. control group; 2p — significance vs. control doum group; 3p — significance vs. diabetic nephropathy (DN) 
group; 4p — significance vs. prophylactic group; N = 10 for each group
Figure 2. Comparison of serum levels of insulin, C-peptide, cystatin C 
and neutrophil gelatinase-associated lipocalin (NGAL) in different 
studied groups. 
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with Hyphaene thebaica, caspase-3 showed a mild 
immunoreaction (Fig. 6C), while in the diabetic group 
treated with Hyphaene thebaica, caspase-3 showed 
moderate to strong expression in terms of an im-
munoreaction (Fig. 6D). 
The immunoexpression of desmin was revealed to 
be negatively expressed in the control group (Fig. 7A), 
whereas the untreated DN group showed a strong 
expression of desmin (Fig. 7B). Lastly, while the group 
protected from DN demonstrated a mild reaction to 
desmin (Fig. 7C), the DN-treated group showed mo-
derate to strong desmin expression (Fig. 7D). 
A significant elevation in the caspase-3 area per-
centage and the desmin area percentage was found in 
the untreated DN, prophylactic, and curative groups 
compared with the control group. Treatment with 
Hyphaene thebaica in the prophylactic and curative 
groups induced a significant decrease in caspase-3 
area percentage and desmin area percentage com-
pared with the untreated DN group, yet the formers’ 
levels remained significantly higher than in the control 
group. Lastly, a significant decrease in caspase-3 area 
percentage and the desmin area percentage was 
found in the prophylactic group compared with the 
curative group (Table 3, Fig. 8).
DISCUSSION
Hyphaene thebaica contains different flavonoids 
in its active water-soluble fraction, such as luteolin 
and chrysoeriol, which help in the improvement of 
glucose and insulin tolerance. Luteolin inhibits alp-
ha-glucosidase and alpha-amylase, resulting in the 
decrease of postprandial hyperglycaemia, which redu-
ces rises in blood glucose and significantly decreases 
blood glycosylated haemoglobin levels [34].
In the present study, glucose levels are increased 
with a decrease in insulin levels. These results were 
attributed to the fact that type 2 diabetes mellitus 
was linked to reduced insulin release or insulin resi-
stance, impaired glucose, lipid metabolisms, as well 
as activation of oxidative stress indices [4, 31].
The administration of Hyphaene thebaica led 
to elevated renal function parameters, indicating 
renal impairments. Wang et al. [45] found similar 
results with luteolin, one of the active flavonoids 
found in Hyphaene thebaica, which prevented the 
development of DN by reducing levels of urea and 
creatinine [35, 45]. 
Glomerular dysfunction and tubulointerstitial da-
mage are considered essential in the pathogenesis 
and progression of DN. For these, tubular damage 
Figure 3. A. Photomicrograph of kidney section of control group showed normal architecture; glomerulus (G), parietal layer (black arrow), 
visceral layer (white arrow), proximal (P) and distal (D) convoluted tubules, nucleus of podocyte (curved arrow) and urinary space (US);  
B. Diabetic nephropathy revealed apparently increased size of glomeruli (G) with congested capillary vessels (white arrowhead), vacuolar 
degeneration of the tubules (V), hyaline casts (star), and areas of extravasated blood cells (black arrow); C. Group protected from diabetic 
nephropathy showed nearly normal renal architecture; D. Diabetic nephropathy treated with Hyphaene thebaica revealed no observable  
improvement. Scale bar 20 µm.
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Table 3. Mean diameter of renal corpuscle and urinary space by µm and mean area percentage of caspase-3 expression and desmin
Control group DN group Prophylactic group Curative group
Renal corpuscle diameter [µm] 
(n = 50)
83.848 ± 4.054 85.584 ± 2.785 82.668 ± 5.212 82.592 ± 4.729
1p < 0.033 1p = 0.147 1p = 0.123
2p < 0.0001 2p < 0.0001
3p = 0.925
Urinary space diameter [µm] 
(n = 50)
7.751 ± 0.521 7.683 ± 0.647 7.849 ± 0.497 7.839 ± 0.552
1p = 0.515 1p = 0.357 1p = 0.407
2p = 0.117 2p = 0.140
3p = 0.925
Caspase-3 area [%] 
(n = 10)
0.562 ± 0.283 6.542 ± 0.290 1.015 ± 0.005 5.531 ± 0.224
1p < 0.0001 1p < 0.0001 1p < 0.0001
2p < 0.0001 2p < 0.0001
3p < 0.0001
Desmin area [%] 
(n = 10)
0.586 ± 0.081 5.014 ± 0.714 1.097 ± 0.229 4.051 ± 0.739
1p < 0.0001 1p < 0.017 1p < 0.0001
2p < 0.0001 2p < 0.0001
3p < 0.0001
 Values are presented as mean ± standard deviation; 1p — significance vs. control group; 2p — significance vs. diabetic nephropathy (DN) group; 3p — significance vs. prophylactic group 
Figure 4. The mean diameter of renal corpuscle and urinary space 
compared with the control group.
markers, such as serum and urinary Cys C and NGAL, 
can be used as early predictors of DN [14, 27]. 
Kim et al. [20] found an increased serum Cys C 
in patients with DN, which is in accordance with the 
findings of this study, and Nauta et al. [30] found 
that DN patients have an increased serum levels of 
both serum Cys C and NGAL [5, 30]. 
In the current work, serum NGAL levels were fo-
und to be significantly elevated in the untreated DN 
group. These results are in agreement with other 
researches [8, 38]. Many studies have concluded that 
oxidative stress caused by hyperglycaemia enhances 
diabetic complications, including DN and progress 
toward end-stage renal disease [12].
In the current study, the administration of Hyp-
haene thebaica was found to induce a decrease in 
renal damage biomarkers Cys C and NGAL. This was 
attributed to the rich amount of flavonoids found 
in Hyphaene thebaica, which inhibits lipid oxidation 
by scavenging free radicals or by other mechanisms, 
such as singlet oxygen quenching, metal chelation, 
and lipoxygenase inhibition [2]. Hsu et al. [15] have 
shown that the aqueous extract of Hyphaene thebaica 
possesses an antioxidant activity due to its substantial 
amount of water-soluble phenolic content.
In support of the findings of the current study, 
DN alterations were found to occur at the Bowman’s 
capsule, including thickening of the basal lamina of 
the parietal layer, glomerular capillaries, and me-
sangial expansion [13]. The current research found 
tubular alterations in the untreated DN group in the 
form of dilatation, vacuolation of the tubular cell 
lining, and hyaline casts, as well as capillary con-
gestion and apparent fibrosis. All of these results 
are in accordance with the research of others [19]. 
These structural changes could be attributed to hy-
perglycaemia, which might initiate apoptosis due to 
454
Folia Morphol., 2015, Vol. 74, No. 4
Figure 6. Caspase-3 immunoexpression; A. Control group showed weak immunostaining; B. Diabetic nephropathy group revealed strong 
caspase-3 expression; C. Mild caspase-3 immunostaining expression in the group protected from diabetic nephropathy; D. Moderate to 
strong expression of caspase-3 immunostaining (black arrow) in diabetic nephropathy treated group. Scale bar 20 µm. 
Figure 5. A. Photomicrograph of kidney section of control group showed minimal collagen fibres in the glomeruli (G), Bowman’s capsule 
(black arrow) and around the tubules (white arrow); B. Diabetic nephropathy revealed condensation of collagen fibres in the glomeruli (G), 
with apparently thickened parietal layer of Bowman’s capsule (black arrow), convoluted tubules (white arrows), and congested blood vessels 
(C) and vacant area between some tubular cells and basal lamina (curved arrow); C. Group protected revealed minimal intraglomerular (G) 
collagen fibres with no change in the basal lamina thickness (black arrow) and no notable change in convoluted tubules (white arrow);  
D. Diabetic nephropathy treated showed collagen in the glomeruli (G), surrounding Bowman’s capsule (black arrow) and the tubules  
(white arrow). Note thickening of the capillary walls (white arrowhead). Masson’s trichrome, Scale bar 20 µm.
mitochondrial dysfunction, increased intracellular 
Ca2+, and oxidative stress [43]. Obliteration of the 
capillary lumen observed in a previous research has 
been associated with mesangial expansion, which 
leads to the reduction of the renal filtration area, 
and consequently, glomerular function cessation [33]. 
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In the current work, the untreated DN group de-
monstrated an increased collagen fibre deposition 
in the mesangial matrix and around the glomerular 
capillaries. The collagen which came from plasma 
exudation or was created by mesangial cells [44] 
might be attributed to hyperglycaemia. Hypergly-
caemia leads to increased fibronectin production in 
response to damage, and fibronectin attracts fibrin, 
which is essential in cell-collagen interaction and 
collagen deposition [24]. 
Caspases are cysteine aspartyl-specific protea-
ses, and caspase-3 is the main effector caspase in 
the detection of renal apoptosis and necrotic cell 
populations [25, 26]. In the current work, caspase-3 
expression was found to be increased in the untreated 
DN group and significantly diminished by Hyphaene 
thebaica, especially if used as a protective. The strong 
expression of caspase-3 is related to cellular damage 
or cellular death, which are considered the main re-
asons for diabetic complications [11]. In accordance 
with our findings, apoptotic changes have been ob-
served in glomeruli, proximal, and distal convoluted 
tubular cells [22]. 
It is well known that podocyte number, density, 
and proteinuria are closely related [7]. Podocyte injury 
is always the target of glomerular affection and is 
involved in the progress of glomerular diseases [10]. 
In the current work, in accordance with the study by 
Fioretto and Mauer [13], extensive podocyte dama-
ge was detected in Bowman’s corpuscles in terms 
of desmin expression. Increased desmin expression 
is commonly noticed in many glomerular diseases, 
especially when podocytes are injured [47]. These 
injuries can be attributed to the dedifferentiation 
of the podocyte epithelium accompanied by the ini-
tiation of mesenchymal indicators, such as desmin 
[23]. Podocytes may undergo mesenchymal trans-
Figure 8. The mean area percentage of caspase-3 expression and 
desmin compared with the control group.
Figure 7. Desmin immunoexpression; A. Control group showed weak immunostaining; B. Diabetic nephropathy group revealed strong desmin 
expression; C. Mild desmin immune expression in the group protected from diabetic nephropathy; D. Moderate to strong expression of desmin 
immunostaining (black arrow) in diabetic nephropathy treated group. Scale bar 20 µm. 
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ition and dedifferentiation of the epithelium due to 
the rise of transforming growth factor beta-1, and 
therefore the expression of desmin can be considered 
a trusted applicable indicator for podocyte epithelial 
and mesenchymal transition [23]. Podocyte injury 
may be caused by renin–angiotensin–aldosterone and 
endothelin systems, increased profibrotic cytokines 
release, elevated protein kinase C, and non-enzymatic 
glycosylation [9].
CONCLUSIONS
In conclusion, the results of this study suggest that 
Hyphaene thebaica can be advised as a protective 
plant for diabetics to delay the progression of diabetic 
renal complications. 
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